WARREN ONG: Open Payments
NPI 1003896101 · CRANSTON, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$128,195 in 157 payments from 11 companies in 2025. Trend: 2023 $148,207 · 2024 $98,692 · 2025 $128,195
Speaker / faculty: $88,399Consulting: $21,355Travel & lodging: $14,216Food & beverage: $4,225
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 83 | $83,990 |
| Neurocrine BioSciences, Inc. | 34 | $32,268 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $9,565 |
| Teva Pharmaceuticals USA, Inc. | 3 | $1,958 |
| Otsuka America Pharmaceutical, Inc. | 7 | $158 |
| ABBVIE INC. | 3 | $84 |
| Alkermes, Inc. | 3 | $78 |
| Lundbeck LLC | 2 | $37 |
| Braeburn Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: COBENFY, INGREZZA, CAPLYTA, AUSTEDO XR, REXULTI, ABILIFY MAINTENA, VRAYLAR, ARISTADA.
Industry payments across RI — which companies pay providers there.
